Autologous platelet rich plasma injection can be effective in the management of osteoarthritis of the knee: impact on IL-1 β, TNF-α, hs-CRP.
Autologous PRP injection
Biomarkers
Knee joint function
Knee osteoarthritis
Motor function
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
22
06
2024
accepted:
06
09
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
To analyze the clinical efficacy of autologous platelet rich plasma (PRP) injection in the treatment of knee osteoarthritis (KOA) and its influence on related biomarkers such as interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP). 150 study subjects are randomly selected from KOA patients received treatment in the Third Hospital of Bethune Hospital from January 2022 to January 2023. After enrollment, patients are randomly numbered 1-100. 75 patients with odd and even numbers are included in the control group and the observation group, respectively. The former is cured with etocoxib, while the latter is treated with autologous PRP injection based on this. The clinical efficacy, relevant biomarkers (IL-1β, TNF-α, hs-CRP), and Lysholm knee score scale and Fugl Meyer assessment (FMA) scores are compared and analyzed. The total effective rate of 94.67% (71/75) in the observation group was higher than 84.00% (63/75) in the other one group (P < 0.05). Before treatment, the comparison in IL-1β, TNF-α, hs-CRP, Lysholm knee joint score, and FMA scale score are with P > 0.05. When the treatment period is at 1 and 2 months, the IL-1β, TNF-α, hs-CRP levels within the group were lower than before treatment, while the Lysholm knee joint score and FMA scale score were higher than before treatment (P < 0.05). When the treatment period is at 1 and 2 months, the IL-1β, TNF-α, hs-CRP levels and the Lysholm knee joint and FMA scale scores in the observation group were lower and higher than those in the other one group, respectively (P < 0.05). The application of autologous PRP injection therapy in KOA patients can significantly improve their levels of related biomarkers, effectively improve knee joint function and motor function, and have good clinical efficacy.
Identifiants
pubmed: 39478604
doi: 10.1186/s13018-024-05060-9
pii: 10.1186/s13018-024-05060-9
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Interleukin-1beta
0
Tumor Necrosis Factor-alpha
0
Biomarkers
0
IL1B protein, human
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
703Informations de copyright
© 2024. The Author(s).
Références
Geng R, Li J, Yu C, Zhang C, Chen F, Chen J, Ni H, Wang J, Kang K, Wei Z, Xu Y, Jin T. Knee osteoarthritis: current status and research progress in treatment (review). Exp Ther Med. 2023;26(4):481.
doi: 10.3892/etm.2023.12180
pubmed: 37745043
pmcid: 10515111
Nelligan RK. Appraisal of clinical practice guideline: National Institute for Health and Care Excellence (NICE) clinical practice guideline for osteoarthritis in over 16s: diagnosis and management. J Physiother. 2023;69(3):196.
doi: 10.1016/j.jphys.2023.04.002
pubmed: 37263908
Sellam J, Courties A, Eymard F, Ferrero S, Latourte A, Ornetti P, Bannwarth B, Baumann L, Berenbaum F, Chevalier X, Ea HK, Fabre MC, Forestier R, Grange L, Lellouche H, Maillet J, Mainard D, Perrot S, Rannou F, Rat AC, Roux CH, Senbel E, Richette P, French Society of Rheumatology. Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis. Joint Bone Spine. 2020;87(6):548–55.
doi: 10.1016/j.jbspin.2020.09.004
pubmed: 32931933
Stoddart JC, Dandridge O, Garner A, Cobb J, van Arkel RJ. The compartmental distribution of knee osteoarthritis—a systematic review and meta-analysis. Osteoarthr Cartil. 2021;29(4):445–55.
doi: 10.1016/j.joca.2020.10.011
Jang S, Lee K, Ju JH. Recent updates of diagnosis, pathophysiology, and treatment on osteoarthritis of the knee. Int J Mol Sci. 2021;22(5):2619.
doi: 10.3390/ijms22052619
pubmed: 33807695
pmcid: 7961389
Primorac D, Molnar V, Rod E, Jeleč Ž, Čukelj F, Matišić V, Vrdoljak T, Hudetz D, Hajsok H, Borić I. Knee osteoarthritis: a review of pathogenesis and state-of-the-art non-operative therapeutic considerations. Genes (Basel). 2020;11(8):854.
doi: 10.3390/genes11080854
pubmed: 32722615
Schmidt M, Sørensen HT, Pedersen L. Cardiovascular risks of diclofenac versus other older COX-2 inhibitors (meloxicam and etodolac) and newer COX-2 inhibitors (celecoxib and etoricoxib): a series of nationwide emulated trials. Drug Saf. 2022;45(9):983–94.
doi: 10.1007/s40264-022-01211-1
pubmed: 35909207
Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292(4):557–74.
doi: 10.1111/joim.13505
pubmed: 35585779
Anil U, Markus DH, Hurley ET, Manjunath AK, Alaia MJ, Campbell KA, Jazrawi LM, Strauss EJ. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: a network meta-analysis of randomized controlled trials. Knee. 2021;32:173–82.
doi: 10.1016/j.knee.2021.08.008
pubmed: 34500430
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–33. https://doi.org/10.1002/art.41142 . Erratum in: Arthritis Rheumatol. 2021;73(5):799.
doi: 10.1002/art.41142
pubmed: 31908163
pmcid: 10518852
Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578–89.
doi: 10.1016/j.joca.2019.06.011
Celik D, Coşkunsu D, Kiliçoğlu O. Translation and cultural adaptation of the Turkish Lysholm knee scale: ease of use, validity, and reliability. Clin Orthop Relat Res. 2013;471(8):2602–10.
doi: 10.1007/s11999-013-3046-z
pubmed: 23666590
pmcid: 3705057
Singer B, Garcia-Vega J. The Fugl-Meyer upper extremity scale. J Physiother. 2017;63(1):53.
doi: 10.1016/j.jphys.2016.08.010
pubmed: 27964964
Gupta A, Potty AG, Maffulli N. Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis. Front Pain Res (Lausanne). 2023;4:1216190.
doi: 10.3389/fpain.2023.1216190
pubmed: 37396144
Shang V, Li J, Little CB, Li JJ. Understanding the effects of mesenchymal stromal cell therapy for treating osteoarthritis using an in vitro co-culture model. Eur Cell Mater. 2023;45:143–57.
doi: 10.22203/eCM.v045a10
pubmed: 37335111
Wang Y, Li D, Lv Z, Feng B, Li T, Weng X. Efficacy and safety of Gutong Patch compared with NSAIDs for knee osteoarthritis: a real-world multicenter, prospective cohort study in China. Pharmacol Res. 2023;197:106954.
doi: 10.1016/j.phrs.2023.106954
pubmed: 37832860
Andia I, Atilano L, Maffulli N. Biological targets of multimolecular therapies in middle-age osteoarthritis. Sports Med Arthrosc Rev. 2022;30(3):141–6.
doi: 10.1097/JSA.0000000000000349
pubmed: 35921596
Tucker JD, Goetz LL, Duncan MB, Gilman JB, Elmore LW, Sell SA, McClure MJ, Quagliano PV, Martin CC. Randomized, placebo-controlled analysis of the knee synovial environment following platelet-rich plasma treatment for knee osteoarthritis. PM R. 2021;13(7):707–19.
doi: 10.1002/pmrj.12561
pubmed: 33492733
Meert L, Mertens MG, Meeus M, Vervullens S, Baert I, Beckwée D, Verdonk P, Smeets RJEM. Identification of metabolic factors and inflammatory markers predictive of outcome after total knee arthroplasty in patients with knee osteoarthritis: a systematic review. Int J Environ Res Public Health. 2023;20(10):5796.
doi: 10.3390/ijerph20105796
pubmed: 37239524
pmcid: 10218133
Ruan G, Xu J, Wang K, Wu J, Zhu Q, Ren J, Bian F, Chang B, Bai X, Han W, Ding C. Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis. Osteoarthr Cartil. 2018;26(8):1063–9.
doi: 10.1016/j.joca.2018.05.003
Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794.
doi: 10.3390/ijms21207794
pubmed: 33096812
pmcid: 7589810
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021;14(1):97–108.
doi: 10.1080/17474086.2021.1860002
pubmed: 33275468
Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013;9(12):721–30.
doi: 10.1038/nrrheum.2013.141
pubmed: 24080861
Peng GL. Platelet-rich plasma for skin rejuvenation: facts, fiction, and pearls for practice. Facial Plast Surg Clin N Am. 2019;27(3):405–11.
doi: 10.1016/j.fsc.2019.04.006
Everts PA, van Erp A, DeSimone A, Cohen DS, Gardner RD. Platelet rich plasma in orthopedic surgical medicine. Platelets. 2021;32(2):163–74.
doi: 10.1080/09537104.2020.1869717
pubmed: 33400591
Andia I, Sánchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther. 2012;12(1):7–22.
doi: 10.1517/14712598.2012.632765
pubmed: 22171664